Maternal, fetal and perinatal alterations associated with obesity, overweight and gestational diabetes: an observational cohort study (PREOBE) by Berglund, Staffan K. et al.
RESEARCH ARTICLE Open Access
Maternal, fetal and perinatal alterations
associated with obesity, overweight and
gestational diabetes: an observational
cohort study (PREOBE)
Staffan K. Berglund1,2, Luz García-Valdés1, Francisco J Torres-Espinola1, Mª Teresa Segura1,
Cristina Martínez-Zaldívar1, María J. Aguilar1, Ahmad Agil3, Jose A. Lorente4, Jesús Florido5, Carmen Padilla5,
Signe Altmäe1,6, Acensión Marcos7, M. Carmen López-Sabater8, Cristina Campoy1,6* and on behalf of the PREOBE
team
Abstract
Background: Maternal overweight, obesity, and gestational diabetes (GD) have been negatively associated with
offspring development. Further knowledge regarding metabolic and nutritional alterations in these mother and
their offspring are warranted.
Methods: In an observational cohort study we included 331 pregnant women from Granada, Spain. The mothers
were categorized into four groups according to BMI and their GD status; overweight (n:56), obese (n:64), GD (n:79),
and healthy normal weight controls (n:132). We assessed maternal growth and nutritional biomarkers at 24 weeks
(n = 269), 34 weeks (n = 310) and at delivery (n = 310) and the perinatal characteristics including cord blood
biomarkers.
Results: Obese and GD mothers had significantly lower weight gain during pregnancy and infant birth weight,
waist circumference, and placental weight were higher in the obese group, including a significantly increased
prevalence of macrosomia. Except for differences in markers of glucose metabolism (glucose, HbA1c, insulin and
uric acid) we found at some measures that overweight and/or obese mothers had lower levels of transferrin
saturation, hemoglobin, Vitamin B12 and folate and higher levels of C-reactive protein, erythrocyte sedimentation
rate, ferritin, and cortisol. GD mothers had similar differences in hemoglobin and C-reactive protein but higher
levels of folate. The latter was seen also in cord blood.
Conclusions: We identified several metabolic alterations in overweight, obese and GD mothers compared to
controls. Together with the observed differences in infant anthropometrics, these may be important biomarkers in
future research regarding the programming of health and disease in children.
Trial registration: The trial was registered at clinicaltrials.gov, identifier (NCT01634464).
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Background
The concept of early programming of child health is an
established and highly relevant research field [1–4]. Nu-
merous experimental and epidemiological studies have
shown that nutritional alterations in pre-, peri-, and
postnatal stages of life may have a significant impact on
the future health and development on a child. Associa-
tions have been found into adulthood with metabolic
diseases, neurodevelopmental impairments, cancer, and
immunological function alterations [2, 4, 5]. Obesity
during pregnancy is one of the most established risk fac-
tors for negative long-term programming. In addition to
its short term risks such as preterm birth, and macro-
somia [6, 7], obesity have also been associated with
increased risks of metabolic and immunological dys-
functions and of poor neurodevelopment [4, 5, 8–11].
Considering that a large proportion of women of re-
productive age in developed countries enter preg-
nancy being overweight or obese, and the numbers
are increasing, these described associations constitute
a threat to future child health [12].
To better understand the intrauterine programming
following maternal obesity, more knowledge is required.
Obesity is closely correlated to the metabolic complica-
tion gestational diabetes (GD) and therefore, alterations
in glucose regulation have been proposed as a candidate
explaining the mechanism [13, 14]. It is unclear whether
the previously observed correlations are applicable to
non-diabetic overweight or obese pregnancies. Several
other possible risk factors of non-optimal maternal me-
tabolism or nutrition have also been proposed, such as
maternal weight gain during pregnancy [15], alterations
in the regulation of folate [16] or leptin [17], deficiency
of vitamin D [18] or iron [19, 20], or influences of the
fatty acids profiles [21, 22]. But for the most, the exact
role of these biomarkers is still left to explore, since
most previous research is based on retrospective epi-
demiological studies. There is also a lack of knowledge
on how these metabolic markers actually differ between
healthy mothers and those with overweight, obesity, and
GD respectively.
To add knowledge to the field of early program-
ming following maternal metabolic pathologies, we
designed the PREOBE trial, with the overall objectives
to establish a cohort of mother-child pairs and ex-
plore the short- and long-term effects of maternal
overweight, obesity and GD compared to controls, on
peri- and postnatal outcomes in the mother and her
offspring. Maternal nutritional biomarkers, placental
function and growth were monitored during preg-
nancy as well as the short- and long-term health and
development of the offspring. In the present paper,
we aimed to describe the methodology and baseline
outcomes of the PREOBE study.
Methods
Study design and subjects
This study was designed as a prospective observational
cohort study and included no interventions. The study
recruitment was performed between 2008 and 2012,
through a collaboration with the Clinical University
Hospital San Cecilio and the Mother-Infant University
Hospital of Granada, Granada, Spain and their periph-
eral health centers. Pregnant women attending antenatal
clinics for regular check-up were approached by study
staff and invited to participate in the study. The inclu-
sion criteria were: single pregnancy at 12–34 weeks of
gestation (preferably before 20 weeks), age between 18
and 45 years, no simultaneous participation in any other
research study, no drug treatment, no vegan diet, and no
diagnosed diseases other than obesity, overweight or ges-
tational diabetes. In total 474 pregnant women were
assessed for eligibility. Nineteen did not meet the inclu-
sion criteria, 15 due to pre-gestational diabetes and 4
due to underweight, and 124 did not come back for the
first study visit (without stating why). The 124 cases of
early drop were mostly normal weight mothers without
GD (n = 107) but they were similar in age and educa-
tional level with those who remained. Of the 331 in-
cluded mothers, 269 were included before 24 weeks of
gestation. However, due to the lack of mothers diag-
nosed with GD at that early part of gestation, another 62
were recruited after 24 weeks (Fig. 1). All included
women were allocated into four different groups based
on the calculated pre-gestational body mass index (BMI)
and the gestational diabetic status at 34 weeks:
1. Normal weight (18.5 ≤ BMI < 25 and no diagnosed
gestational diabetes), n = 132
2. Overweight (25 ≤ BMI <30 and no diagnosed
gestational diabetes), n = 56
3. Obese (BMI ≥30 and no diagnosed gestational
diabetes), n = 64
4. Gestational diabetes (and BMI ≥18.5), n = 79
We actively searched for mothers in the latter three
groups, and the GD group included both mothers who
had already been diagnosed with GD and by those from
the first three groups who developed GD between re-
cruitment and 34 weeks and accordingly switched group.
The diagnosis of GDM was made by the local clinicians
at the hospital and was based on an oral glucose toler-
ance test (OGTT), interpreted according to the National
Diabetes Data Group criteria [23] and the Third Inter-
national Workshop-Conference on Gestational Diabetes
Mellitus [24]. To increase the sample size, we included
mothers from all three weight categories. Consequently,
the GD-group included women with normal weight
(n = 32), overweight (n = 23), and obesity (n = 24). According
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to the local hospital routines at time of the study, the
mothers diagnosed with GD were offered to participate
in an endocrine-nutritional programme to optimize
glucose control using nutritional and lifestyle recom-
mendations. In some cases they received medical treat-
ment including oral antidiabetics or insulin therapy if
they needed it. This intervention was not part of the
present study and neither monitored individually. The
overweight and obese mothers without GD received no
similar intervention.
Ethics, consent and permissions
The project was approved by the Bioethical Committees
for Clinical Research of the Clinical University Hospital
San Cecilio and the Mother-Infant University Hospital
of Granada, Granada, Spain. An ethical approval was
also obtained by the Research Bioethical Committee of
the University of Granada. Written informed consent
was obtained from all participants at study entry, and
after received full information from a research group
member.
Data collection during pregnancy
The data collection procedures during pregnancy and at
delivery are summarized in Table 1. At the recruitment
visit, information was collected regarding maternal pre-
pregnancy weight, used for calculation of the pre-
pregnancy BMI, and sociodemographic and medical
background including ethnicity, education, age, number
of previous pregnancies/children, smoking habits, and
alcohol consumption. The pregnant women were also
asked about prior or current supplements of vitamins or
Fig. 1 Trial profile. 1 Of the 269 mothers included before 24 weeks, 248 remained at delivery and were analyzed in the present paper including
247 blood samples. 2 At 34 weeks, 21 had dropped out and 5 cases abstained the visit, two of them due to preterm birth. Blood was drawn in
304 mothers. 3 At delivery, 245 cases called the study staff to collect blood samples from mothers (219) and umbilical cord (186), and placental
samples (236). For remaining cases, only delivery record data was collected
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minerals. At 24 and 34 weeks of gestation, all pregnant
mothers enrolled were called back for a visit including
an anthropometric revision, bio-impedance measure-
ments, and collection of maternal venous blood, urine,
cheek cell and fecal samples. The fecal samples were an-
alyzed for microbiota as has been described elsewhere
[25]. Furthermore, maternal dietary habits and physical
activity were recorded by several questionnaires, and
fetal growth and development was assessed by ultra-
sound measurements.
Data collection at delivery
All participating mothers were instructed to contact the
study center at the time of admission at the delivery
ward. Whenever possible, study staff attended the deliv-
ery and measured the placental weight and circumfer-
ence and collected cord blood and placental samples,
immediately after cord clamping. Furthermore at deliv-
ery, a venous blood puncture was drawn from the
mother. Maternal weight at delivery was collected from
medical records and weight gain during pregnancy
calculated. Maternal data collection also included a re-
peated follow up until 18 months of life including postpar-
tum questionnaire, anthropometric and bio-impedance
measures, dietary records, and in a subsample also breast
milk samples.
With regard to the offspring, the following perinatal
data was collected at time of delivery: infant gender,
gestational age at birth, infant anthropometrics including
head, chest, mid-arm, and abdominal circumference,
hip-knee, knee-heal, admission to neonatal ward, Apgar
score, and mode of delivery (vaginal or caesarian sec-
tion). Whenever possible, the offspring’s meconium and
feces at different visits within the follow-up were col-
lected and stored for gut microbiota study. Finally at
birth, cheek cells were collected and stored at − 80°. The
latter have been analyzed for fatty acid profiles, and dif-
ferent polymorphisms in genes including FADS and
ELOVs and PPRG [26].
Laboratory analyses
The maternal blood samples from 24 weeks, 34 weeks,
and delivery as well as the umbilical cord blood were an-
alyzed for hematologic and biochemical markers at the
laboratory of Clinical University Hospital “San Cecilio”,
Granada, Spain including the following: Hematological
parameters (Hemoglobin [Hb] and mean corpuscular
volume [MCV]), erythrocyte sedimentation rate (ESR),
Table 1 Schedule of data collection, assessments and laboratory analyses in mothers and offspring in the PREOBE-study
Measure Outcomes Time of collection
Baseline recruitment information Pre-gestational BMI, ethnicity, medical history, age, education,
parity, smoking, ongoing supplements
Recruitment visit, 24 wk, and 34 wk
Maternal anthropometrics Weight, length, circumference of abdomen, waist etc., skinfold
thickness of triceps, subscapularis etc.a
24 wk, 34 wk
Bioimpedance BMRa, impedancea, BMIa, FM/FMIa, FFM/FFMIa, body watera 24 wk, 34 wk
Fetal ultrasound Fetal anthropometricsa 24 wk, 34 wk
Urine samples Metabolomicsa 24 wk, 34 wk
Fecal samples Microbiotab, metabolomicsa 24 wk, near delivery
Cheek cell sample Microbiotaa, geneticsab, fatty acidsa 34 wk (mother), birth (infant)
Food questionnaire Quantitative and qualitative dietary analysesa 24 wk, 34 wk
Placenta samples Placental weight and circumference, Lipid profilea, phospholipidsa,
gene expressiona, lipid peroxidation, pTfRb
Delivery
Lifestyle questionnaire Lifestyle and physical activitya 24 wk
Blood samples (Mother and cord blood) Direct analyses: ESR, glucose, lipidsa, urea, creatinine, uric acid,
bilirubin, iron status, folate, TSH, amylase, CRP, HbA1c, total protein,
albumin, vit B12, insulin, cortisol, IGF1a, IGFBP1a, and lymphocyte
subpopulationsa. Frozen serum/plasma: Hepcidinb, TfRb, adiponectina,
resistina, leptin, interleukinsa, phospholipid profilesa, lipid peroxidationa,
tocopherola, retinola.
24 wk, 34 wk, delivery (mother
and cord blood)
Perinatal records Gender, gestational age, Apgar, delivery mode, neonatal
diagnoses/admission
–
Infant anthropometrics Birth weight, length, circumference of head, upper-arm, chest and
waist, BMI, waist/height index, heel-knee, hip-knee
Birth
Meconium Microbiotaa Birth
Breast milk Fatty acidsa, vitaminsa day 1, day 7, day 30
aUnpublished data
bPublished elsewhere
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serum biomarkers (glucose, cholesterol, creatinine, uric
acid, ferritin, transferrin, transferrin saturation [TS], fol-
ate, thyroid − stimulating hormone [TSH], C-reactive
protein [CRP], HbA1c, vitamin B12, insulin, and corti-
sol). The analyses also included fatty acids profile in
plasma phospholipids. Apart from direct analyses above,
we analyzed lymphocyte subpopulations and serum and
plasma aliquots were also stored at −80 °C for later ana-
lyses as described in Table 1. The placental samples were
analyzed for fatty acids content, lipid pro-oxidation,
phospholipid profiles, and expression of placental key
genes related to energy, proteins, carbohydrates, iron
and fatty acids transport and metabolism. The results
are partly published elsewhere [20, 27, 28].
Statistics
All statistical analyses were performed using the SPSS
statistical software package for Windows (version 22.0;
IBM SPSS Inc., Chicago, IL, USA). Continuous, normally
distributed variables were displayed as mean and stand-
ard deviation (SD) and explored by analysis of variance,
while variables showing skew distribution were pre-
sented as median and inter quartile range (IQR) and an-
alyzed using non-parametric rank sum tests. We used
ANOVA, Kruskal-Wallis rank sum test, or Chi square
test to compare the four PREOBE-groups. The compari-
sons were performed without confounder adjustment. In
outcomes with group size in the overweight or obese
group less than 20, the two groups were combined to-
gether resulting in three groups to compare. In case of
significant group differences, a post hoc test was used to
explore the overweight, obese and gestational diabetic
groups against the normal group. The post hoc tests
were adjusted for multiple comparisons by multiplying
the p-value with the number intergroup comparisons
(two or three). P-values < 0.05 were considered statisti-
cally significant.
Results
From the 331 pregnant women included in the current
study, 21 dropped out before the visit at 34 weeks.
Another 5 of them did not attend the visit at 34 weeks
(two of them due to preterm delivery) but remained in
the study for postnatal follow-ups. Thus, 310 mother-
child pairs were considered as remaining at delivery and
included in the analyses of the present paper. The com-
pliance to participate at each visit was generally low and
furthermore, some women occasionally refused blood
sampling. The number of cases visiting the study center,
as well as the number of blood samples drawn is de-
scribed in Fig. 1. At time of delivery, we were only able
to participate for data collection in a subsample due to
the fact that the mothers forgot to contact the research
team at time of delivery. Cord blood sampling was
further limited in numbers due to the tight time limit to
perform the collection.
Maternal characteristics and outcomes
The background and baseline characteristics of the
mothers who completed the study, together with their
laboratory and anthropometric outcomes are shown in
Table 2. With regard to the sociodemographic back-
ground, we found that GD mothers were significantly
older than the controls (multiple comparison adjusted
value [adj. p] was <0.001). Furthermore, the obese group
had generally lower prevalence of university education
(adj. p <0.001). However, no significant differences were
found in ethnicity, parity, smoking or alcohol intake.
The average weight gain during pregnancy was signifi-
cantly lower in the obese (adj. p <0.001) and diabetic
(adj. p <0.001) groups. The reported intake of supple-
ments before study entry was generally high. We found
a significantly lower proportion of mothers in the obese
group reporting intake of folic acid (adj. p = 0.015) and
higher proportions of mothers in the GD group report-
ing intake of B12 (adj. p = 0.039).
The biochemical variables differed significantly in sev-
eral measures. TS, Hb, vitamin B12, folate, and cortisol
were lower in the overweight or obese group at some
time-points, while ferritin, CRP, ESR, uric acid, HbA1c,
and insulin showed higher levels in obese and/or over-
weight mothers compared to controls. The GD group
showed lower values of Hb but higher levels in folate,
CRP, ESR, glucose, and in HbA1c. Regarding creatinine
and TSH no significant differences nor trends of differ-
ences were observed.
Perinatal outcomes and cord blood analyses
The perinatal data collected at delivery are presented
in Table 3. The obese group had significantly higher pla-
cental (adj. p <0.001), and infant weight (adj. p = 0.003)
but also higher placental/fetal weight ratio (adj. p = 0.018).
The prevalence of macrosomia, defined as birth
weight >4000 g was significantly higher in the obese
group compared to the normal group with an odds
ratio (95 % CI) of 4.6 (1.4–14.9), adj. p = 0.018. Also
the mean infant waist circumferences (adj. p = 0.028)
and chest circumferences (adj. p = 0.020) were higher
in the obese group. The diabetic group had a higher
prevalence of caesarian delivery (adj. p = 0.038) and the in-
fants had a higher weight/height ratio (adj. p = 0.032). We
observed no significant differences between any groups in
gestational age at birth or in prevalence of preterm birth
or LBW.
ESR in cord blood was only measured in one infant
from the normal group and for this reason we could not
analyze this variable. Remaining laboratory measures
from cord blood are shown in Table 4. Although the
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Table 2 Baseline characteristics, anthropometrics, and laboratory measures during pregnancy for the 310 mothers who remained in
the PREOBE trial at delivery
Time N Normal weight
n = 128
Overweight
n = 54
Obese
n = 52
Gestational diabetes
n = 76
P
Background
Age (y) 20 wk 310 30.9 ± 4.2 32.0 ± 4.2 29.5 ± 7.8 33.7 ± 4.6a <0.001
Parity (>1) – 306 55 (43.3 %) 24 (45.3 %) 28 (53.8 %) 35 (47.3 %) 0.637
Smoking during pregnancy – 268 17 (14.4 %) 5 (10.2 %) 7 (15.6 %) 7 (12.3 %) 0.850
Alcohol during pregnancy – 270 6 (5.1 %) 1 (2.0 %) 1 (2.2 %) 3 (5.3 %) 0.692
Education at university-level – 306 68 (53.5 %) 22 (41.5 %) 11 (21.2 %)a 27 (36.5 %) <0.001
Supplements during pregnancy
Iron supplementation – 280 46 (36.2 %) 13 (28.9 %) 10 (21.7 %) 28 (45.2 %) 0.065
Folic acid supplementation – 260 115 (92.7 %) 38 (84.4 %) 32 (76.2 %)a 43 (87.8 %) 0.036
B12 supplementation – 259 64 (51.6 %) 22 (48.9 %) 22 (52.4 %) 35 (72.8 %)a 0.055
Anthropometrics
Pre-gestational BMI (kg/m2) 0 wk 310 22.0 ± 1.7 23.7 ± 1.3a 33.3 ± 2.8a 27.7 ± 6.2a <0.001
Weight (kg) 0 wk 310 59.1 ± 5.6 72.3 ± 6.0a 87.3 ± 9.1a 72.5 ± 18.3a <0.001
delivery 209 72.0 ± 8.8 82.2 ± 7.8a 94.8 ± 11.3a 77.9 ± 16.1a <0.001
Weight gain during pregnancy (kg) delivery 209 12.5 ± 6.1 10.3 ± 5.2 7.2 ± 6.9a 6.9 ± 8.2a <0.001
Iron status
Ferritin (μg/l) 24 wk 240 18.3 (10–26) 18.3 (10–28) 22.7 (16–41)a 23.0 (18–30) 0.033
34 wk 299 15.7 (9–21) 12.0 (9–19) 12.8 (9–18) 16.4 (11–29) 0.011
delivery 199 21.0 (16–33) 19.6 (16–26) 17.4 (15–22) 22.0 (18–46) 0.005
TS (%) 24 wk 242 18.9 ± 8.6 16.6 ± 6.3 15.3 ± 5.4a 20.3 ± 7.7 0.009
34 wk 300 17.1 ± 10.9 14.9 ± 7.9 12.5 ± 5.2a 19.0 ± 13.7 0.006
delivery 200 17.6 ± 12.4 16.4 ± 11.9 13.9 ± 6.0 17.4 ± 8.4 0.376
Hb (g/l) 24 wk 222 12.6 ± 1.6 12.4 ± 1.7 12.1 ± 0.4 11.6 ± 0.8 0.136
34 wk 288 11.8 ± 1.2 11.5 ± 1.5 11.6 ± 0.8 11.8 ± 1.1 0.421
delivery 199 12.6 ± 2.0 11.4 ± 1.4a 11.4 ± 1.4a 11.6 ± 1.7a <0.001
MCV (fl) 24 wk 222 88.9 ± 4.4 88.9 ± 4.7 88.0 ± 4.1 89.3 ± 4.3 0.617
34 wk 288 87.3 ± 5.5 87.0 ± 5.4 85.4 ± 4.1 86.6 ± 5.1 0.193
delivery 198 86.2 ± 6.9 84.6 ± 5.3 84.1 ± 5.3 87.7 ± 4.9 0.036
Vitamins
Vitamin B12 (pg/ml) 24 wk 59 321 ± 124 262 ± 76 309 ± 136 0.156
34 wk 87 257 ± 91 248 ± 68 307 ± 101 0.012
delivery 59 312 ± 98 221 ± 73a 263 ± 90 0.037
Folate (ng/ml)b 24 wk 242 15.3 (11.5–19.3) 16.3 (10.5–19.7) 14.4 (8.4–19.8) 18.1 (13.4–20.0) 0.212
34 wk 300 14.8 (10.2–18.0) 13.5 (7.4–19.2) 11.4 (6.2–16.3)a 18.2 (12.3–20.0)a <0.001
delivery 201 14.2 (9.1–18.3) 10.1 (6.0–17.4) 7.3 (5.0–14.6)a 15.1 (9.6–19.0) 0.001
Other biomarkers
Glucose (g/l) 24 wk 242 80.5 ± 16.6 87.3 ± 16.6 84.8 ± 16.7 97.2 ± 24.4a <0.001
34 wk 301 86.7 ± 18.6 88.0 ± 17.7 89.6 ± 17.8 93.5 ± 23.5 0.119
delivery 201 82.7 ± 28.0 86.8 ± 23.7 96.9 ± 35.3 102.2 ± 33.8a 0.002
Insulin (μU/ml) 24 wk 104 21.8 (6.6–39.1) 36.5 (14.1–66.2) 26.9 (16.9–54.3) 21.0 (14.1–60.8) 0.306
34 wk 159 29.9 (12.9–51.4) 38.9 (24.3–63.3) 38.4 (22.8–71.0) 24.5 (12.5–42.1) 0.013
delivery 110 10.0 (5.4–15.7) 14.6 (10.7–27.5)a 12.1 (6.7–23.0) 0.008
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overweight and obese groups were combined, the num-
ber of analyzed cases was low, and no significant differ-
ences were observed in the overweight/obese group
compared to the normal group. There was an overall
group differences in Vitamin B12-levels and a trend sug-
gesting lower levels in the overweight/obese group.
However, only 3 cases were analyzed in the normal
group and consequently the difference did not reach sig-
nificance (adj. p = 0.4). Similarly, due to low numbers an-
alyzed, there was a non-significant trend of higher
glucose and HbA1c-levels in cord blood from the GD-
group (adj. p = 0.160 and 0.074 respectively). The only
significant post-hoc comparison was observed in folate
which was higher in the GD-group compared to controls
(adj. p = 0.024).
Discussion
In the present paper we explored maternal and perinatal
alterations in pregnancies following maternal over-
weight, obesity and GD, all suggested risk factors of
non-optimal programming of long-term child health. In
agreement with our hypothesis, we observed several sig-
nificant differences compared to controls. All three
groups of mothers showed significant differences in
levels of some of the metabolic biomarkers explored.
The infants born to the obese mothers differed in their
anthropometrics including higher birth—and placental
weight and higher placental-neonatal weight ratio. They
also had a higher risk of macrosomia, while the offspring
born to women with GD showed no anthropometric
differences compared to controls. The cord blood ana-
lyses were limited due to sample size and we found only
that offspring born to GD mothers had higher levels of
folate and a non-significant trend of higher glucose and
HbA1c.
The maternal group differences observed in the
present paper were mostly in accordance with previous
research. The GD mothers had significantly higher age.
This is a previously well described correlation [29] and
may be an important confounding factor in long term
studies of the offspring. Regarding maternal anthropo-
metrics, we found slower weight gain during pregnancy
in obese mothers as it has been previously described
[30]. This is of clinical importance since it has been
shown that maternal overweight/obesity and weight gain
during pregnancy are both and independently associated
Table 2 Baseline characteristics, anthropometrics, and laboratory measures during pregnancy for the 310 mothers who remained in
the PREOBE trial at delivery (Continued)
HbA1c (%) 24 wk 196 4.2 (4.0–4.4) 4.5 (4.2–4.9)a 4.8 (4.2–5.1)a 5.1 (4.6–5.3)a <0.001
34 wk 258 4.5 (4.3–4.8) 4.8 (4.4–5.4)a 5.0 (4.5–4.4)a 5.1 (4.7–5.5)a <0.001
delivery 180 4.6 (4.4–4.8) 5.0 (4.7–4.3)a 5.2 (4.5–5.5)a 5.2 (4.9–4.5)a <0.001
Uric acid (mg/dl) 24 wk 243 3.09 ± 0.62 3.06 ± 0.75 3.53 ± 0.72a 3.08 ± 0.51 <0.001
34 wk 301 3.62 ± 0.77 3.59 ± 0.91 3.76 ± 0.69 3.87 ± 1.04 0.186
delivery 200 4.55 ± 1.08 4.64 ± 1.41 4.64 ± 1.22 4.45 ± 0.96 0.843
Creatinine (mg/dl) 24 wk 230 0.60 ± 0.14 0.59 ± 0.10 0.56 ± 0.10 0.58 ± 0.09 0.239
34 wk 301 0.61 ± 0.11 0.71 ± 0.62 0.59 ± 0.11 0.66 ± 0.15 0.087
delivery 201 0.64 ± 0.11 0.69 ± 0.19 0.61 ± 0.13 0.68 ± 0.17 0.096
TSH (ng/ml) 24 wk 241 1.65 (0.98–2.08) 1.37 (1.06–2.18) 1.65 (1.11–2.32) 1.56 (1.17–2.50) 0.888
34 wk 299 1.39 (1.05–2.04) 1.34 (1.08–1.98) 1.59 (0.89–2.17) 1.39 (1.04–2.07) 0.954
delivery 200 2.24 (1.61–3.16) 2.15 (1.66–2.88) 2.09 (1.59–3.06) 2.17 (1.43–2.92) 0.781
CRP (mg/dl) 24 wk 71 0.27 (0.16–0.34) 0.42 (0.17–0.53)a 0.68 (0.35–0.90)a <0.001
34 wk 121 0.79 (0.43–1.2) 0.65 (0.39–1.0)a 0.96 (0.66–2.5) 0.005
delivery 89 0.56 (0.27–0.82) 0.45 (0.28–0.83)a 1.2 (0.52–2.9)a 0.042
ESR (mm) 24 wk 91 35.7 ± 16.7 47.6 ± 16.3a 47.7 ± 14.3a 49.4 ± 20.1a 0.020
34 wk 136 47.9 ± 25.9 60.8 ± 12.4 55.0 ± 11.6 53.2 ± 19.0 0.118
delivery 103 39.6 ± 22.9 54.0 ± 22.9 47.3 ± 24.0 0.060
Cortisol (μg/dl) 24 wk 104 21.0 ± 6.2 18.3 ± 5.7 17.1 ± 5.0a 19.5 ± 5.4 0.050
34 wk 160 22.6 ± 6.7 23.3 ± 6.4 23.3 ± 6.6 22.6 ± 7.1 0.934
delivery 112 57.5 ± 26.5 42.0 ± 15.2a 48.6 ± 18.2 0.007
Data are mean ± SD, n (%), or median (IQR) and p-values are ANOVA, Chi square test, or Kruskal Wallis rank sum test respectively
aSignificantly different from normal group in a multiple-comparison-adjusted-post hoc test (p-value was multiplied with the number of post hoc analyses [two
or three])
bHighest detectable folate level was 20 ng/ml
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with increased obesity in the offspring [15]. Considering
these observations, we find it relevant to follow the
present cohort and explore how the maternal age and
weight gain during pregnancy correlates to later health
markers of the offspring in the four groups respectively.
Higher glucose and HbA1c-levels in the mothers of
the GD group were expected by definition. We also ob-
served higher insulin and HbA1c-levels in the over-
weight and obese mothers, suggesting alterations also in
their glucose metabolism. Interestingly, there was a
trend of higher glucose and HbA1c also in the cord
blood of diabetic offspring. Since insulin and HbA1c are
not transferred to the fetus and maternal insulin has lit-
tle effect on the placenta, the observation is most likely
explained by differences in glucose transfer [14]. More
specifically, it is suggested that higher glucose levels in
the mother causes relatively higher levels in the fetus
and consequently affect its metabolism. The relevance of
these non-significant observations are unclear, however
they are concurrent with the ‘in utero’ hypothesis,
suggesting that an increased intrauterine exposure to
glucose occurs in the fetus if the levels are altered in the
mother. This hypothesis has been considered an
important key to the long-term risk for obesity [31], and
we plan to analyze the correlation with long term health
outcomes in the children of the PREOBE cohort.
Overweight and obesity are also associated with in-
creased risk of iron deficiency [32], another well ex-
plored candidate for unfavorable perinatal programming
[33]. Thus, the observed lower levels of TS, Hb, and fer-
ritin at delivery were not unexpected but nevertheless
interesting considering future neurodevelopmental as-
sessments of the present cohort. The higher levels of
ferritin at 24 weeks most likely reflect an increased in-
flammatory response in early pregnancy as discussed
below. This and other analyses of iron metabolism in the
obese group are further discussed and explored else-
where [20], and we plan long-term follow ups to assess
its impact on offspring neurodevelopment.
Our results demonstrated lower levels of vitamin B12
and folate in obese mothers compared to controls. This
may partly be explained by differences in ongoing or
recently discontinued intake of supplements at inclusion,
but it may also reflect differences in dietary habits.
Nevertheless, this observation is interesting and we
found few previous assessments of vitamin B levels in
Table 3 Perinatal outcomes in pregnancies following maternal overweight, obesity, or gestational diabetes compared to controls
N Normal weight
n = 128
Overweight
n = 54
Obese
n = 52
Gestational diabetes
n = 76
P
Mode of delivery (vaginal) 228 95 (87.2 %) 31 (72.1 %) 26 (72.2 %) 28 (70.0 %)a 0.036
Placental weight (g) 227 475 ± 112 512 ± 123 571 ± 133a 517 ± 116 0.001
Placental /fetal-ratio 226 0.147 ± 0.03 0.158 ± 0.04 0.164 ± 0.04a 0.155 ± 0.03 0.030
Apgar score at 5 min 234 10 (10–10) 10 (10–10) 10 (10–10) 10 (10–10) 0.357
Gestational age at birth (wk) 287 39.4 ± 1.2 39.5 ± 1.4 39.8 ± 1.4 39.2 ± 1.5 0.169
Preterm birth (<37 wk) 287 2 (1.6 %) 1 (2.0 %) 2 (4.2 %) 1 (1.5 %) 0.740
Post term birth (>42 wk) 287 2 (1.6 %) 0 (0 %) 3 (6.3 %) 1 (1.5 %) 0.148
Infant gender (boy) 298 61 (48.8 %) 25 (48.1 %) 29 (59.2 %) 43 (59.7 %) 0.327
Infant birth weight (kg) 301 3.25 ± 0.39 3.29 ± 0.49 3.49 ± 0.51a 3.31 ± 0.46 0.020
Low birth weight (<2500 g) 301 5 (3.9 %) 2 (3.8 %) 0 (0 %) 2 (2.8 %) 0.567
Macrosomia (>4000 g) 301 5 (3.9 %) 6 (11.3 %) 8 (16.3 %)a 3 (4.2 %) 0.016
Infant birth length (cm) 236 50.4 ± 1.9 50.5 ± 1.6 51.0 ± 2.3 50.1 ± 2.4 0.192
Infant BMI (m/kg2) 236 13.0 ± 1.2 13.0 ± 1.3 13.3 ± 1.4 13.3 ± 1.6 0.464
Infant waist/height index 142 0.64 ± 0.04 0.64 ± 0.05 0.66 ± 0.05 0.67 ± 0.04a 0.023
Infant head circumference (cm) 200 34.4 ± 1.3 34.5 ± 1.1 34.4 ± 1.6 37.7 ± 1.4 0.606
Waist circumference (cm) 147 32.3 ± 1.9 32.4 ± 2.3 33.7 ± 2.6a 33.3 ± 1.9 0.014
Upper arm circumference (cm) 191 10.9 ± 1.0 11.3 ± 1.4 11.3 ± 1.2 11.3 ± 1.2 0.214
Chest circumference (cm) 161 33.0 ± 1.9 33.1 ± 2.7 34.4 ± 2.4a 33.5 ± 1.6 0.031
Hip-knee length (cm) 188 11.0 ± 1.1 10.9 ± 1.1 10.8 ± 1.4 10.8 ± 1.2 0.916
Knee-heal length (cm) 190 10.7 ± 1.1 10.8 ± 1.0 11.2 ± 1.1 11.2 ± 1.4 0.074
Admission to neonatal ward 270 11 (9.2 %) 0 (0 %) 2 (4.3 %) 2 (3.4 %) 0.098
Data are mean ± SD, n (%), or median (IQR) and p-values are ANOVA, Chi square test, or Kruskal Wallis rank sum test respectively
aSignificantly different from normal group in a multiple-comparison-adjusted-post hoc test
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obese and diabetic mothers to compare with. In one
Vietnamese observational trial, authors found no associ-
ation between BMI and B12 or folate [34]. Our findings
are of high clinical interest since deficiencies in both vi-
tamins are associated with maternal as well as offspring
morbidity [35]. Folate deficiency is a risk factor for
neural tube defects but it is also attributed a key role in
fetal programming, due to its role in DNA-methylation
[16]. Lower levels of vitamin B12 are associated with in-
creased risk of neural tube defect, adiposity, increased
insulin resistance, impaired neurodevelopment and al-
tered risk of cancer in the offspring [36]. A correlation
between maternal and infant B12-status was recently
verified in a randomized trial from Bangladesh, suggest-
ing that altering levels in the mother can affect the fetus
[37]. Furthermore, a recent in vitro study showed that
placental trophoblasts from GD mothers are less func-
tional and sensitive to alterations in the mother and that
leptin may inhibit their transport [38]. Considering these
findings, the above described clinical relevance of B12,
and the here observed differences in obese mothers, we
hypothesize that un-optimal homeostasis of vitamin B12,
may be an important mechanism behind negative long
term effects following obese pregnancies. Further studies
of the mechanisms for vitamin B transport in general
and for mothers with obesity and/or GD may give fur-
ther clues to early programming and are urgently war-
ranted in this and other cohorts. Interestingly, even
though they included overweight and obese mothers, the
GD group in the present study had levels of B12 that
were similar to the controls. Most likely, this is due to
the local routine of offering nutritional counseling to
mothers diagnosed with GD, a hypothesis supported by
the higher prevalence of B12 supplementation.
Another expected maternal biochemical characteristic
was the increased inflammatory response, presented
through higher levels of CRP at all measures and of ESR
at 24 weeks of gestation both in the overweight/obese
mothers and in those with GD. This finding is in accord-
ance with the present literature regarding obesity, which
states that obesity is an inflammatory disease [39]. The
clinical relevance for these small differences is unclear.
However, it has been discussed that inflammation is a
potential mechanism for un-optimal fetal development
in obese pregnancies [40] and the results here supports
further studies of this field.
The overall aim of the PREOBE project is to explore
the effect of these maternal metabolic pathologies in the
offspring. In the present paper, we analyzed the birth
characteristics and found that the infants born from
obese mothers had significantly higher birth weight and
waist circumference while the infants born from mothers
with GD had higher waist/height index compared to
controls. Of most clinical relevance was an increased
risk of macrosomia in the offspring of obese mothers.
Furthermore, there were significant differences between
Table 4 Cord blood analyses
N Normal weight
n ≤ 76
Overweight or obese
n ≤ 62
Gestational diabetes
n ≤ 45
P
Iron status
Ferritin (μg/l) 119 168 (103–265) 163 (115–233) 139 (88–268) 0.930
TS (%) 49 60.7 ± 2.1 55.1 ± 17.7 64.3 ± 20.0 0.254
Hb (g/l) 125 16.7 ± 1.6 17.0 ± 2.4 16.3 ± 2.1 0.359
MCV (fl) 125 107.5 ± 5.4 107.0 ± 6.5 107.9 ± 3.7 0.776
Vitamins
Vitamin B12 (pg/ml) 45 665 ± 512 436 ± 198 739 ± 333 0.005
Folate (ng/ml)b 150 >20 (16.6– > 20) 19.9 (15.5– > 20) >20 (>20– > 20)a 0.010
Other biomarkers
Glucose (g/l) 156 69.7 ± 21.1 66.2 ± 22.2 77.4 ± 22.4 0.050
Insulin (μU/ml) 118 3.5 (2.2–5.8) 4.4 (2.9–7.3) 5.6 (2.0–10.3) 0.126
HbA1c (%) 34 3.2 (3.0–3.5) 3.3 (3.2–3.5) 3.7 (3.3–4.4) 0.064
Uric acid (mg/dl) 132 4.92 ± 0.90 4.95 ± 1.29 4.94 ± 1.06 0.995
Creatinine (mg/dl) 131 0.60 ± 0.18 0.63 ± 0.23 0.61 ± 0.21 0.712
TSH (ng/ml) 133 11.0 (7.3–15.3) 8.4 (6.3–14.4) 8.1 (5.5–12.2) 0.270
CRP (mg/dl) 47 0.00 (0.00–0.10) 0.01 (0.00–0.03) 0.01 (0.07–0.10) 0.308
Cortisol (μg/dl) 47 13.6 ± 4.5 13.7 ± 10.3 11.6 ± 5.7 0.678
Data are mean ± SD, n (%), or median (IQR) and p-values are ANOVA, Chi square test, or Kruskal Wallis rank sum test respectively
aSignificantly different from normal group in a multiple-comparison-adjusted-post hoc test
bHighest detectable folate level was 20 ng/ml
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the groups on chest circumference, showing a trend of
higher levels in the obese group, even if these did not
reach significance in the post hoc analyses. Altogether,
the results suggest that the maternal obesity and GD
contribute to small but nevertheless significant over-
nutrition, further supporting the hypothesis that excess
of “fuel” during pregnancy contributed to increased
growth in the fetus [41]. This observation of birth
weight is in line with several previous epidemiological
trials [15]. We also observed a higher placental/neonatal
weight ratio in the obese mothers which might suggest
that placental function is compromised [42]. Other re-
searchers have also observed increased prevalence of
preterm delivery [6]. In the present paper, we found no
such increased risk, possible explained by overall low
prevalence (1.5–4.2 %). Neither did we observe a signifi-
cant difference in infant BMI or gestational age.
A limitation with the study presented here is the het-
erogeneity among the mothers with GD. First, they were
included in the same group independently of BMI and
interactions with BMI may occur in the outcomes from
this group. Secondly, the GD mothers were offered indi-
vidualized nutritional recommendations and we have
limited individual information regarding the compliance
to this. Additional stratification of the GD mothers
would have strengthened the study further but due to
low sample size, we chose not to do it in the present
analyses. Nevertheless, the GD group of the present
study represent a common group of mothers in daily
clinical practice and further knowledge regarding their
metabolism during pregnancy as well as the health of
their offspring, is relevant from a clinical perspective.
Furthermore, since the groups were only compared to
controls, the finding in the overweight and obese groups
can be interpreted without a similar risk of interaction
with GD. Other limitations of the study are the poor
compliance rate. The dropout rate at each time of meas-
ure was high, particularly at delivery, and apart from
lower power in our statistical analyses, the representa-
tiveness of the cohort may be reduced.
The main limitation of the present study is the obser-
vational design which does not allow inference of causal-
ity behind the observed differences and confounding e.g.
from socioeconomic factors and normal fluctuations
during pregnancy, may have occurred. However, the
aims of the present baseline analyses were to identify dif-
ferences and to generate candidates for future research.
In that perspective, we find the results interesting and
relevant. We explored our cohort using a wide variety of
biomarkers and other assessments and found several in-
teresting alterations that might hold important clues to
the programming mechanisms, whether they are con-
founded by other factors or not. E.g., the observations in
B12 levels are not described previously and prompt
important future research. Above, we discussed the ob-
servations made in the present analyses, but due to the
amount of data recorded, we also aim further secondary
analyses to explore and discuss each group of bio-
markers in detail. Furthermore, due to stored serum,
placental samples, and DNA, the study enables future
additional analyses. But above all, due to the planned fol-
low ups, we are able to explore their correlation to long
term health in the offspring.
Conclusions
Maternal overweight, obesity and GD are associated with
alterations in nutrition, anthropometrics, and biochem-
ical markers of the pregnant women. The effect on the
fetus is yet unclear but we observed higher body weight
and increased risk of macrosomia in the offspring to
mothers with obesity. Based on the alterations observed
and previous research of early programming, we identi-
fied several possible candidates for future research in-
cluding; markers of glucose metabolism, inflammation,
and iron status, and levels of vitamin B12 and folate. Ex-
cept for mechanistic studies, there is a need of long-
term studies aiming to explore if any of these markers
are associated with long term health in the offspring. To
contribute, we plan to follow the PREOBE cohort up to
7.5 years of age.
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